



首页

最新一期

期刊动态

过刊浏览

医学视频

在线投稿

期刊检索

期刊订阅

合作科室

注册
登录

您的位置: [首页](#)>> [文章摘要](#)

急性肺血栓栓塞症危险分层与治疗研究进展

朱光发, 习昕

100029 首都医科大学附属北京安贞医院呼吸与危重症医学科

朱光发, Email: gfzhu6388@sina.com

关键词: 肺血栓栓塞症

[评论](#) [收藏](#) [全](#)

文献标引: 朱光发, 习昕. 急性肺血栓栓塞症危险分层与治疗研究进展[J/CD]. 中华临床医师杂志: 电子版, 2013

[复制](#)

参考文献:

[1] Torbicki A, Perrier A, Konstantinides SV, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J, 2008, 29: 2276-2315.

[2] Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive acute pulmonary embolism: a statement from the American Heart Association. Circulation, 2011, 123: 1788-1830.

[3] Kenron C, Aki EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: American College of Chest Physicians Evidence-Based Clinical Practice Guideline. Chest, 2012, 141: e419S-e494S.

[4] Donzé J, Le Gal G, Fine MJ, et al. Prospective validation of the Pulmonary Embolism Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost, 2008, 100: 1383-1389.

[5] Jimenez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med, 2010, 170: 1383-1389.

[6] Sanchez O, Trinquart L, Colombet I, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J, 2012, 33: 1569-1577.

[7] Kreit JW. The impact of right ventricular dysfunction on the prognosis and outcome of normotensive patients with pulmonary embolism. Chest, 2004, 125: 1539-1545.

期刊导读

7卷16期 2013年8月 [最新]

期刊存档

期刊存档

[查看目录](#)

期刊订阅

[在线订阅](#)

[邮件订阅](#)

[RSS](#)

作者中心

[资质及晋升信息](#)

[作者查稿](#)

[写作技巧](#)

[投稿方式](#)

[作者指南](#)

编委会

期刊服务

[建议我们](#)

[会员服务](#)

[广告合作](#)

[继续教育](#)

[8] Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. *Cardiol*, 2005, 20: 496–501.

[9] Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prognosis of acute pulmonary embolism and its impact on outcome in patients with pulmonary embolism: a systematic review and meta-analysis. *Crit Care Med*, 2008, 178: 425–430.

[10] Jimenez D, Uresandi F, Otero R, et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and meta-analysis. *Chest*, 2009, 135: 1037–1044.

[11] Lankeit M, Friesen D, Aschoff J, et al. Highly sensitive troponin T assay in patients with acute pulmonary embolism. *Eur Heart J*, 2010, 31: 1836–1844.

[12] Lankeit M, Jimenez D, Kostrubiec M, et al. Predictive value of the highly sensitive troponin T assay and the simplified Pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. *Circulation*, 2011, 124: 2716–2722.

[13] Dellas C, Puls M, Lankeit M, et al. Elevated heart-type fatty acid-binding protein 3 levels at hospital admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. *Cardiol*, 2010, 55: 2150–2157.

[14] Lankeit M, Kempf T, Dellas C, et al. Growth differentiation factor-15 for prognosis in patients with acute pulmonary embolism. *Am J Respir Crit Care Med*, 2008, 177: 1011–1016.

[15] Lankeit M, Gomez V, Wagner C, et al. A strategy combining imaging and laboratory tests for risk stratification: comparison with a simplified clinical score for risk stratification of patients with acute pulmonary embolism. *Chest*, 2012, 141: 916–922.

[16] Wan S, Quinlan DJ, Agnelli G, et al. Thrombolysis compared with heparin for the treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. *Stroke*, 2009, 40: 744–749.

[17] Stein PD, Matta F, Steinberger DS, et al. Intracerebral hemorrhage with thrombolysis for acute pulmonary embolism. *Am J Med*, 2012, 125: 50–56.

[18] Stein PD, Matta F. Case fatality rate with pulmonary embolectomy for acute pulmonary embolism. *Am J Med*, 2012, 125: 471–477.

[19] Kuo WT, Gould MK, Louie JD, et al. Catheterdirected therapy for the treatment of acute pulmonary embolism: systematic review and meta-analysis of modern techniques. *J Vasc Med Biol*, 2009, 20: 1431–1440.

[20] Carrier M, Le GG, Wells PS, et al. Systematic review: case-fatality rates of acute pulmonary embolism and major bleeding events among patients treated for venous thromboembolism. *Am J Med*, 2010, 152: 578–589.

[21] Stein PD, Matta F, Keyes DC, et al. Impact of vena cava filters on in-hospital mortality in patients with acute pulmonary embolism. *Am J Med*, 2012, 125: 478–484.

[22] Wang C, Zhai Z, Yang Y, et al. Efficacy and safety of low dose recombinant tissue plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized controlled trial. *Chest*, 2010, 137: 254–262.

[23] Ross AM, Gao R, Coyne KS, et al. A randomized trial confirming tIle efficacy of recombinant tissue plasminogen activator in a Chinese myocardial infarction population: superiority to usual dose urokinase: the TUCC trial. *Am Heart J*, 2001, 142: 244-247.

[24] The PEITHO Steering Committee. Single-bolus tenecteplase plus heparin compared with alteplase alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis Trial. *Am Heart J*, 2012, 163: 33-38.

[25] Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment of acute pulmonary embolism: an international, openlabel, randomised, non-inferiority trial. *Lancet*, 2013, 378: 41-48.

[26] Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for acute pulmonary embolism in older Americans. *N Engl J Med*, 2011, 365: 2002-2012.

[27] Sconce E, Avery P, Wynne H, et al. Vitamin K supplementation can improve steady-state anticoagulation for patients with unexplained variability in response to warfarin. *Thromb Haemostasis*, 2011, 111: 2419-2423.

[28] Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. *Nat Rev Clin Sci*, 2009, 30: 375-386.

[29] Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin (CoumaGen-II). *Circulation*, 2012, 125: 1997-2005.

[30] Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med*, 2010, 363: 2499-2510.

[31] Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of acute venous thromboembolism. *N Engl J Med*, 2012, 366: 1287-1297.

[32] Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med*, 2009, 361: 2342-2352.

[33] Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1626 patients. *Haematologica*, 2007, 92: 199-205.

[34] Goldhaber SZ, Piazza G. Optimal duration of anticoagulation after venous thromboembolism. *Circulation*, 2011, 123: 664-667.

[35] Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. *Thromb Haemostasis*, 2011, 121: 1630-1636.

[36] Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. *N Engl J Med*, 2012, 366: 1959-1967.

[37] Becker RC. Aspirin and the prevention of venous thromboembolism. *N Engl J Med*, 2013, 369: 2030-2036.

急性肺血栓栓塞症危险分层与治疗研究进展

朱光发, 习昕. . 中华临床医师杂志: 电子版
2013;7(15):6783-6787.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

冠心病合并肺血栓栓塞症诊治策略

熊长明, 胡恩慈. . 中华临床医师杂志: 电子版
2013;7(15):6788-6791.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

肺栓塞诊治研究进展

刘双. . 中华临床医师杂志: 电子版
2013;7(15):6792-6794.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

慢性阻塞性肺疾病合并肺栓塞的现状与诊治需关注的问题

何志义, 钟小宁. . 中华临床医师杂志: 电子版
2013;7(15):6795-6797.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

肺栓塞常见诊治误区

吴炳祥, 孙娜. . 中华临床医师杂志: 电子版
2013;7(15):6798-6800.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

肺血栓栓塞症的二次溶栓治疗

蒋军广, 黄永杰. . 中华临床医师杂志: 电子版
2013;7(15):6801-6803.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

肺栓塞的诊治

刘蕾, 马壮. . 中华临床医师杂志: 电子版
2013;7(15):6804-6806.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

肺血栓栓塞症全面防治中抗凝药物的合理使用

罗华. . 中华临床医师杂志: 电子版
2013;7(15):6807-6810.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

应加强对肺血栓栓塞症患者隐源性肿瘤的筛查

许建英. . 中华临床医师杂志: 电子版
2013;7(15):6811-6812.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)